INTRODUCTION
The risk-benefit ratio of small-volume packed red blood cell (svPRBC) transfusions in neonates has not been fully established. Although the concern of a direct transmission of an infectious agent remains paramount to parents, other potential risks, such as the concomitant delivery of cytokines released from WBCs, have not been fully investigated using current recommended blood banking techniques.
Studies in adults do not support ''routine'' PRBC transfusions to maintain a predetermined hemoglobin level based upon a failure to demonstrate a benefit of maintaining hemoglobin goals for critical care survival and the potential increased risks associated with immunomodulation from autologous PRBC transfusions. [1] [2] [3] [4] [5] In premature neonates, transfusions to achieve a specific hemoglobin level per level of illness are still considered a standard of care. This standard was created from existing practices of individuals involved in large multicenter studies involving the use of recombinant human erythropoietin for treatment of anemia in prematurity. 6 There has been no established method to determine when a premature neonate will benefit from a PRBC transfusion. Similarly, there is not a complete understanding of the risks involved with PRBC transfusions.
In the creation of the current neonatal standard, concerns of immunomodulation from transfusions have not been discussed or included in the relative risk F benefit balance. Extrapolation from animal and human adult literature would suggest that the risks extend beyond direct infectious contamination, processing errors, fluid imbalance, or graft vs host disease, to include the potential of immunomodulation. The implications of cytokineinduced immunomodulation in this patient population are significant. Proinflammatory cytokine alterations have been implicated in the pathogenesis of nearly every significant premature neonatal disease process, most notably, in the modulation of brain, lung, and gut injury. Prestorage leukoreduction at the time of donation removes >99% of white blood cells. It is known from previous studies that nonleukoreduced PRBC units contain significant levels of cytokines that can act as a load with the transfusion. The cytokine load associated with PRBC transfusions arises from the release of cytokines from white blood cells not removed prior to banking. Prestorage leukoreduction eliminates PMN as priming compared to standard storage methods. 7 Therefore, newer blood banking techniques may reduce this risk.
Despite the high frequency of PRBC transfusions given to premature neonates, there has been no previous investigation in this population to determine whether the immune and cytokine systems are altered by an svPRBC transfusion. This study seeks to evaluate whether prestorage leukoreduced PRBC transfusions carry a cytokine load and whether this load, if it exists, can induce short-term alterations of cytokine balance in premature neonates. The primary null hypothesis is that there will not be a detectable increase in serum cytokines (TNF-a, IL-1b, IL-6, IL-10) between 1 and 42 days in prestorage leukoreduced dedicated PRBC units. The secondary study hypothesis is that if there is a cytokine load introduced from a small volume PRBC transfusion, it will not significantly alter serum infant cytokines when measured pre-and post-transfusion.
METHODOLOGY
All PRBC units were prestorage leukocyte reduced (Leukotrap BPF4 High Efficiency, Pall Corp.) at the time of donation and preserved with AS-5 (Optisol). Cytokines planned for measurement included IL-6, IL-10, IL-1b, TNF-a, utilizing standard EIA immunoassay. Two milliliters of the PRBC transfusate was analyzed by collection through a sterile docking device at the time of transfusion, and 3, 21, and 42 days of storage age. IRB approval was obtained and informed consent was obtained from parents.
Cytokine samples were maintained at À701C to minimize freeze F thaw cycles until batch testing. Given that 0.8 cm 3 of neonate serum was used, assay ranges were determined for each cytokine test by serial dilutions of a pooled batch of 6 to 8 neonatal serums. Samples were quantitatively analyzed employing sandwich immunoassay technique using Quantikine High Sensitivity immunoassay kits (R&D Systems, Minneapolis, MN) for human tumor necrosis factor alpha (TNF-a; minimal detectable dose (MDD) 0.12 pg/ml), interleukin 6 (IL-6; MDD 0.039 pg/ml), interleukin 10 (IL-10; MDD <0.5 pg/ml), and interleukin 1 beta (IL-1b; MDD <0.1 pg/ml). The absorbance readings were read at appropriate wavelengths using a Titertek Multiskan MCC/340 plate reader with wavelength correction. Sample concentrations were determined by reference to the standard curve and multiplied by the appropriate dilution factor.
As per hospital routine, each AS donated unit is assigned to a specific infant to use until the unit expires at 42 days of age. 8 All svPRBCs were 20 cm 3 /kg and given over a period of 2 to 4 hours. 9 The determination of whether an infant needed a transfusion was based upon clinical reasons independent of this study protocol and usually within the suggested parameters. 7 Infant cytokine analysis occurred by obtaining 0.8 cm 3 of serum (1.6 cm 3 of whole blood) within 6 hours prior to the transfusion and 1-hour post completion of transfusion. The infant study population included infants with a gestational age Z24 weeks and r32 weeks who were older than 24 hours of age and less than 37 weeks postmenstrual age. Informed parental permission was obtained on all infants. Infants with sepsis, immunologic abnormality, necrotizing enterocolitis, or other blood product administration within the previous 7 days were excluded. Epidemiologic information on the pregnancy and neonatal course were collected. Cytokines that were measured include TNF-a, IL-1b, IL-6, and IL-10. PRBC data included age of unit, transfusion time, and frequency.
Statistics
Based upon extrapolation from adult literature, it was estimated that approximately 25 units were required to detect a 25% change in cytokine measurements over the duration of storage. An estimated 50 transfusions would be required to determine a pre-post difference of 25% (a ¼ 0.05, b ¼ 0.20) for IL-6. Preliminary analyses of the data were planned after completion of the primary outcome relating to cytokine changes during PRBC storage. The secondary hypothesis involving infant cytokine alterations was highly dependent upon the presence of clinically significant cytokine transfusion load in the stored units. As expected, the cytokine data were not distributed normally, and nonparametric tests were utilized for these analyses.
RESULTS
In all, 27 PRBC units were followed for serial cytokine analysis for the duration of the unit's shelf life. There were no significant levels of IL-6, IL-10, or TNF-a detected in prestorage leukoreduced PRBC units at any of the major time points: days 3, 21, and 42. There were very low levels of IL-1b detected that did not change over time. Comparatively, these levels are less than detected in healthy preterm infants (3 to 26 pg/ml) or in adult blood stored without leukoreduction (7.9 pg/ml). 10, 11 Median cytokine data is presented in Table 1 .
Measurements of infant serum cytokines pre-post transfusion were halted after preliminary analysis determined that there was no evidence of a detectable cytokine load arising from the stored PRBC unit. Nine infants were entered into the study (mean±SD birth EGA 28±2 weeks; postnatal age (PNA) 25±12 days) at this juncture. There were no significant changes in serum cytokine levels pre-vs post-transfusion (IL-6 p ¼ 0.51, IL-10 p ¼ 0.10, IL-1b p ¼ 0.44, TNF-a p ¼ 0.86) (see Figure 1) . Since there were no clinically significant levels of IL-6, IL-10, IL-1b, or TNF-a measured in the stored PRBC transfusate, case-controlling for the cytokine level in the specific PRBC transfusion was not necessary.
DISCUSSION
This is the first study in premature infants that evaluates the cytokine load and alterations associated with svPRBC transfusions. In adults, nonleukoreduced blood or leukoreduction after prolonged storage contains high levels of cytokines and has been associated with immunomodulation in the recipient and increased risk of sepsis and cytokine-induced injury. [12] [13] [14] [15] Premature infants are susceptible to cytokine-based injury and the risks of transfusion-related immunomodulation are not a usual part of the risk F benefit assessment and discussion made by either the parent or the physician.
This study demonstrates that there is a minimal, if any, cytokine presence when utilizing prestorage leukoreduced PRBCs in dedicated-infant units, even when stored up to 42 days of age. There is no direct load of the cytokines measured (IL-6, IL-10, IL-1b, or TNF-a). There was also no evidence of alterations in cytokines following a PRBC transfusion. When evaluating this Figure 1 . Pre-Post transfusion serum cytokine levels.
interaction at a population level, especially in the complex milieu of the premature infant, our data suggest that prefiltered svPRBC transfusions are unlikely to result in a significant immediate in vitro effect on cytokine balance. It would be inappropriate to extrapolate these findings to PRBC units that are not leukoreduced at the time of transfusion. Leukoreduction at a later storage time will not eliminate cytokines already released by WBC, especially the apoptosis WBC. There has been one large epidemiological study of premature infant outcomes following blood transfusion. This retrospective study compared the time period before and after introduction of universal prestorage leukoreduction in three different sites in Canada. 16 In this study, there was a bias towards the null effect because a large portion of the patients in the nonleukoreduction group received post-storage washed cells. Although there was no reduction of mortality, there was significant reduction in morbidities, including retinopathy of prematurity, bronchopulmonary dysplasia, severe intraventricular hemorrhage and necrotizing enterocolitis following prestorage leukoreduction. The overall reduction of any major NICU morbidity was significantly reduced (adjusted OR 0.31) as was the length of stay. On a need-to-treat basis, there is a reduction of one major morbidity for every 10 infants transfused with prestorage leukoreduced blood. The pan-organ system effects seen in that study suggest a cytokine-induced injury risk now prevented by improved blood-banking methodology.
By comparison, recent experience with leukoreduction and clinical outcomes revealed mixed outcomes in adults. In a large, randomized, prospective study of adults, there was no benefit from leukoreduction seen in mortality, antibiotic use, or costs. 17 However, the leukoreduction group received older blood. Leukoreduction prior to transfusion, but after a period of storage, may reflect an intervention after the cytokines are already released into the transfusate from WBCs. 18 Therefore, there it would not be expected to see a benefit. This contrasts with leukoreduction performed at the time of donation. Age of the transfusate may alter oxygen delivery and storage defects. Combining these studies with different leukoreduction time points may not be optimal in evaluating the efficacy and association between leukoreduction and outcomes.
Further processing can reduce bioactive products that may also be present in transfusions. These include lipopolysaccharidebinding protein and bactericidal permeability-increasing protein as a marker of neutrophil activation. 14, 19 While leukoreduction can perform a 3-log-fold decrease in the WBC concentration, there is not a complete elimination of the WBCs. The lifespan of a WBC is significantly shorter than the storage time period. Factors released from WBC apoptosis remain dormant and refractory to elimination until warmed and transfused. 10 Removing the WBCs prestorage may help reduce cytokines. There is a reduction of IL-6 and IL-8 in prestorage, leukoreduced PRBCs over time, consistent with the concept of cytokine degradation and inadequate production of WBC substrate. [20] [21] [22] Prestorage leukoreduction does not adversely effect the quality of the transfusate, but does have processing and cost effects.
This study provides reassurance that current blood-banking methods, utilizing leukoreduction at the time of donation, are unlikely to result in either the cytokine transfusate load or shortterm serum alterations in cytokine levels that have been associated with transfusion-associated immunomodulation in adults. This study data applies only to svPRBC transfusions that are prestorage leukoreduced. The cytokine safety of PRBC units and associated svPRBC transfusions in neonates that are either not leukoreduced or leukoreduced after a period of storage remains undetermined and is a theoretical risk. The use of only prestorage leukoreduced PRBC units for svPRBC transfusions in premature infants should be considered.
